| Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values BF Krippendorff, R Neuhaus, P Lienau, A Reichel, W Huisinga SLAS Discovery 14 (8), 913-923, 2009 | 153 | 2009 |
| G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells KIE McLuckie, M Di Antonio, H Zecchini, J Xian, C Caldas, ... Journal of the American Chemical Society 135 (26), 9640-9643, 2013 | 151 | 2013 |
| Influence of molecular size on tissue distribution of antibody fragments Z Li, BF Krippendorff, S Sharma, AC Walz, T Lavé, DK Shah MAbs 8 (1), 113-119, 2016 | 139 | 2016 |
| Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis BF Krippendorff, K Kuester, C Kloft, W Huisinga Journal of pharmacokinetics and pharmacodynamics 36, 239-260, 2009 | 85 | 2009 |
| Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery BF Krippendorff, P Lienau, A Reichel, W Huisinga Journal of biomolecular screening 12 (1), 92-99, 2007 | 73 | 2007 |
| Quantification of IgG monoclonal antibody clearance in tissues MJ Eigenmann, L Fronton, HP Grimm, MB Otteneder, BF Krippendorff MAbs 9 (6), 1007-1015, 2017 | 61 | 2017 |
| Capacity limits of asialoglycoprotein receptor-mediated liver targeting C Bon, T Hofer, A Bousquet-Mélou, MR Davies, BF Krippendorff MAbs 9 (8), 1360-1369, 2017 | 54 | 2017 |
| Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy F Bauss, M Lechmann, BF Krippendorff, R Staack, F Herting, M Festag, ... Molecular oncology 10 (8), 1317-1329, 2016 | 51 | 2016 |
| Interstitial IgG antibody pharmacokinetics assessed by combined in vivo‐ and physiologically‐based pharmacokinetic modelling approaches MJ Eigenmann, TV Karlsen, BF Krippendorff, O Tenstad, L Fronton, ... The Journal of physiology 595 (24), 7311-7330, 2017 | 48 | 2017 |
| Influence of molecular size on the clearance of antibody fragments Z Li, BF Krippendorff, DK Shah Pharmaceutical research 34, 2131-2141, 2017 | 47 | 2017 |
| Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells Y Lin, FM Richards, BF Krippendorff, JL Bramhall, JA Harrington, ... British journal of cancer 107 (10), 1692-1701, 2012 | 47 | 2012 |
| Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer A Courtin, FM Richards, TE Bapiro, JL Bramhall, A Neesse, N Cook, ... PloS one 8 (6), e67330, 2013 | 37 | 2013 |
| Predicting the F (ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling BF Krippendorff, DA Oyarzún, W Huisinga Journal of pharmacokinetics and pharmacodynamics 39, 125-139, 2012 | 22 | 2012 |
| A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer G Kollmorgen, K Palme, A Seidl, S Scheiblich, F Birzele, S Wilson, ... Scientific reports 7 (1), 18086, 2017 | 14 | 2017 |
| RG7787-a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors G Niederfellner, F Bauss, S Imhof-Jung, F Hesse, S Kronenberg, R Staak, ... Cancer Research 74 (19_Supplement), 4510-4510, 2014 | 9 | 2014 |
| Influence of molecular size on tissue distribution of antibody fragments. MAbs 8, 113–119 Z Li, BF Krippendorff, S Sharma, AC Walz, T Lave, DK Shah | 8 | 2016 |
| Ligand accumulation counteracts therapeutic inhibition of receptor systems BF Krippendorff, D Oyarzún, W Huisinga | 7 | 2009 |
| The EGFR demonstrates linear signal transmission DA Oyarzún, JL Bramhall, F López-Caamal, FM Richards, DI Jodrell, ... Integrative biology 6 (8), 736-742, 2014 | 6 | 2014 |
| Target‐Driven Pharmacokinetics of Biotherapeutics W Huisinga, S Fuhrmann, L Fronton, BF Krippendorff Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and …, 2010 | 3 | 2010 |
| Anti-TPBG antibodies and methods of use S Dengl, S Fenn, J Fischer, T Friess, S Imhof-Jung, B Krippendorff, ... US Patent 10,434,184, 2019 | 2 | 2019 |
Frances RichardsSenior Research Associate at The University of CambridgeVerified email at cruk.cam.ac.uk
